[breadcrumb_custom]

PDS Biotechnology Corporation (NASDAQ:PDSB) At $5.32: What To Do?

In last trading session, PDS Biotechnology Corporation (NASDAQ:PDSB) saw 0.37 million shares changing hands with its beta currently measuring 1.68. Company’s recent per share price level of $5.32 trading at $0.06 or 1.24% at ring of the bell on the day assigns it a market valuation of $165.66M. That closing price of PDSB’s stock is at a discount of -93.05% from its 52-week high price of $10.27 and is indicating a premium of 28.57% from its 52-week low price of $3.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.57 million shares which gives us an average trading volume of 631.42K if we extend that period to 3-months.

PDS Biotechnology Corporation (NASDAQ:PDSB) trade information

Upright in the green during last session for gaining 1.24%, in the last five days PDSB remained trading in the red while hitting it’s week-highest on Thursday, 02/08/24 when the stock touched $5.32 price level, adding 2.03% to its value on the day. PDS Biotechnology Corporation’s shares saw a change of 7.14% in year-to-date performance and have moved -1.57% in past 5-day. PDS Biotechnology Corporation (NASDAQ:PDSB) showed a performance of 8.45% in past 30-days. Number of shares sold short was 5.18 million shares which calculate 8.81 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

PDS Biotechnology Corporation (PDSB) estimates and forecasts

Statistics highlight that PDS Biotechnology Corporation is scoring comparatively lower than the scores of other players of the relevant industry. The company added 11.05% of value to its shares in past 6 months, showing an annual growth rate of -0.70% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 34.30% in the current quarter and calculating -37.50% decrease in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 46.76% during past 5 years.

PDSB Dividends

PDS Biotechnology Corporation is more likely to be releasing its next quarterly report between March 26 and April 01 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders

Insiders are in possession of 4.33% of company’s total shares while institution are holding 25.35 percent of that, with stock having share float percentage of 26.49%. Investors also watch the number of corporate investors in a company very closely, which is 25.35% institutions for PDS Biotechnology Corporation that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at PDSB for having 1.8 million shares of worth $9.6 million. And as of Sep 29, 2023, it was holding 5.80% of the company’s outstanding shares.

The second largest institutional holder is Vanguard Group Inc, which was holding about 1.51 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 4.85% of outstanding shares, having a total worth of $8.03 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2023, the former fund manager was holding 0.85 million shares of worth $4.5 million or 2.72% of the total outstanding shares. The later fund manager was in possession of 0.74 million shares on Dec 30, 2023, making its stake of worth around $3.93 million in the company or a holder of 2.37% of company’s stock.

On Key

Related Posts